Evidence map›Paper›PMID 40820223›Full record

ArticleScientific reports2025

Association between Ki-67 and clinical outcomes in 324 Chinese patients with resectable acral melanoma.

Yi Teng, Jin Wu, Weizhen Zhang, Kui Jiang, Xin Cai, Jianping Gui, Hongfeng Zhou, Yan Wang, Fang Liu, Jiwei Liu and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yi TengCollege of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China.
Jin WuDepartment of Head and Neck Genitourinary Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Weizhen ZhangDepartment of Medical Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Kui JiangDepartment of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Xin CaiDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jianping GuiDepartment of Oncology, Cancer Center, The First Hospital of Jilin University, 1 Xinmin St., Changchun, China.
Hongfeng ZhouDepartment of Head and Neck Genitourinary Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Yan WangDepartment of Medical Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Fang LiuDepartment of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Jiwei LiuDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zhen GuoDepartment of Oncology, Cancer Center, The First Hospital of Jilin University, 1 Xinmin St., Changchun, China.
Hongxue MengDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
Mei XiangDepartment of Medical Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Xiang JiDalian Medical University, Dalian, China.
Di WuDepartment of Oncology, Cancer Center, The First Hospital of Jilin University, 1 Xinmin St., Changchun, China. wudi1971@jlu.edu.cn.ORCID http://orcid.org/0000-0003-1870-798X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between Ki-67 expression and clinical prognosis in patients with resectable acral melanoma (AM) remains unclear. This study explores the prognostic role of Ki-67 in AM using data from 324 patients across five Chinese centers. Patients were divided into low Ki-67 expression and high Ki-67 expression groups based on pathological reports. The log-rank test was used to compare disease-free survival (DFS) and overall survival (OS), and the Cox proportional hazards regression model was employed to identify prognostic factors. Among the 324 patients included in the study, 181 (55.8%) were in the low Ki-67 expression group, and 143 (44.2%) were in the high Ki-67 expression group. The high Ki-67 expression group exhibited a higher incidence of tumor thickness > 4 mm (45.5% vs 24.3%, P < 0.001), ulceration (65.7% vs 54.1%, P = 0.035), stage III (31.5% vs 16.0%, P < 0.001), LDH ≥ 250 U/L (14.0% vs. 6.6%, P = 0.028), and positive sentinel lymph nodes (28.0% vs 11.1%, P = 0.029). High Ki-67 predicted shorter DFS (26.8 vs 74.1 months, P = 0.025) and OS (52.1 months vs NR, P < 0.001). Multivariate analysis identified Ki-67, age, stage and LDH as independent OS predictors.

Indexed as

Ki-67 AntigenMelanomaSkin NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorChinaDisease-Free SurvivalEast Asian PeopleFemaleHumansMaleMiddle AgedPrognosisYoung AdultBiomarkers, TumorKi-67 AntigenAcral melanomaDisease-free survivalKi-67 expressionOverall survival

Identifiers

PMID40820223
PMCPMC12358504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.